Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma.
Friedberg
Jonathan W
JW
D000208:Acute Disease; D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001943:Breast Neoplasms / Q000453:epidemiology / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007558:Italy / Q000453:epidemiology; D007951:Leukemia, Myeloid / Q000453:epidemiology / Q000209:etiology; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008297:Male; D009190:Myelodysplastic Syndromes / Q000453:epidemiology / Q000209:etiology; D009381:Neoplasms, Radiation-Induced / Q000453:epidemiology / Q000209:etiology; D016609:Neoplasms, Second Primary / Q000453:epidemiology / Q000209:etiology; D016499:Radioimmunotherapy / Q000009:adverse effects; D011878:Radiotherapy / Q000009:adverse effects; D014182:Transplantation, Autologous / Q000009:adverse effects; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
D014740:Vidarabine; C024352:fludarabine